167 related articles for article (PubMed ID: 28864682)
21. Everolimus in the treatment of renal cell carcinoma and neuroendocrine tumors.
Chan HY; Grossman AB; Bukowski RM
Adv Ther; 2010 Aug; 27(8):495-511. PubMed ID: 20623346
[TBL] [Abstract][Full Text] [Related]
22. Advances in the systemic treatment of neuroendocrine tumors in the era of molecular therapy.
Leung R; Lang B; Wong H; Chiu J; Yat WK; Shek T; Cho WY; Yau LC; Yau T
Anticancer Agents Med Chem; 2013 Mar; 13(3):382-8. PubMed ID: 23092266
[TBL] [Abstract][Full Text] [Related]
23. Translational Diagnostics and Therapeutics in Pancreatic Neuroendocrine Tumors.
Maxwell JE; Sherman SK; Howe JR
Clin Cancer Res; 2016 Oct; 22(20):5022-5029. PubMed ID: 27742788
[TBL] [Abstract][Full Text] [Related]
24. Mammalian target of rapamycin signaling activation patterns in pancreatic neuroendocrine tumors.
Komori Y; Yada K; Ohta M; Uchida H; Iwashita Y; Fukuzawa K; Kashima K; Yokoyama S; Inomata M; Kitano S
J Hepatobiliary Pancreat Sci; 2014 Apr; 21(4):288-95. PubMed ID: 24002888
[TBL] [Abstract][Full Text] [Related]
25. Successful mTOR inhibitor therapy for a metastastic neuroendocrine tumour in a patient with a germline TSC2 mutation.
Schrader J; Henes FO; Perez D; Burdak-Rothkamm S; Stein A; Izbicki JR; Lohse AW
Ann Oncol; 2017 Apr; 28(4):904-905. PubMed ID: 28327903
[No Abstract] [Full Text] [Related]
26. Pancreatic neuroendocrine tumors: signal pathways and targeted therapies.
Peng L; Schwarz RE
Curr Mol Med; 2013 Mar; 13(3):333-9. PubMed ID: 23331005
[TBL] [Abstract][Full Text] [Related]
27. Everolimus in advanced pancreatic neuroendocrine tumors: the clinical experience.
Yao JC; Phan AT; Jehl V; Shah G; Meric-Bernstam F
Cancer Res; 2013 Mar; 73(5):1449-53. PubMed ID: 23436795
[TBL] [Abstract][Full Text] [Related]
28. Critical focus on mechanisms of resistance and toxicity of m-TOR inhibitors in pancreatic neuroendocrine tumors.
Antonuzzo L; Del Re M; Barucca V; Spada F; Meoni G; Restante G; Danesi R; Di Costanzo F; Fazio N
Cancer Treat Rev; 2017 Jun; 57():28-35. PubMed ID: 28535439
[TBL] [Abstract][Full Text] [Related]
29. Everolimus and pancreatic neuroendocrine tumors (PNETs): Activity, resistance and how to overcome it.
Capozzi M; Caterina I; De Divitiis C; von Arx C; Maiolino P; Tatangelo F; Cavalcanti E; Di Girolamo E; Iaffaioli RV; Scala S; Tafuto S;
Int J Surg; 2015 Sep; 21 Suppl 1():S89-94. PubMed ID: 26123382
[TBL] [Abstract][Full Text] [Related]
30. Phase II Study of BEZ235 versus Everolimus in Patients with Mammalian Target of Rapamycin Inhibitor-Naïve Advanced Pancreatic Neuroendocrine Tumors.
Salazar R; Garcia-Carbonero R; Libutti SK; Hendifar AE; Custodio A; Guimbaud R; Lombard-Bohas C; Ricci S; Klümpen HJ; Capdevila J; Reed N; Walenkamp A; Grande E; Safina S; Meyer T; Kong O; Salomon H; Tavorath R; Yao JC
Oncologist; 2018 Jul; 23(7):766-e90. PubMed ID: 29242283
[TBL] [Abstract][Full Text] [Related]
31. A phase II study of sapanisertib (TAK-228) a mTORC1/2 inhibitor in rapalog-resistant advanced pancreatic neuroendocrine tumors (PNET): ECOG-ACRIN EA2161.
Rajdev L; Lee JW; Libutti SK; Benson AB; Fisher GA; Kunz PL; Hendifar AE; Catalano P; O'Dwyer PJ
Invest New Drugs; 2022 Dec; 40(6):1306-1314. PubMed ID: 36264382
[TBL] [Abstract][Full Text] [Related]
32. Compensatory Increase of Transglutaminase 2 Is Responsible for Resistance to mTOR Inhibitor Treatment.
Cao J; Huang W
PLoS One; 2016; 11(2):e0149388. PubMed ID: 26872016
[TBL] [Abstract][Full Text] [Related]
33. A Phase II Study of BEZ235 in Patients with Everolimus-resistant, Advanced Pancreatic Neuroendocrine Tumours.
Fazio N; Buzzoni R; Baudin E; Antonuzzo L; Hubner RA; Lahner H; DE Herder WW; Raderer M; Teulé A; Capdevila J; Libutti SK; Kulke MH; Shah M; Dey D; Turri S; Aimone P; Massacesi C; Verslype C
Anticancer Res; 2016 Feb; 36(2):713-9. PubMed ID: 26851029
[TBL] [Abstract][Full Text] [Related]
34. Anti-proliferative and anti-secretory effects of everolimus on human pancreatic neuroendocrine tumors primary cultures: is there any benefit from combination with somatostatin analogs?
Mohamed A; Romano D; Saveanu A; Roche C; Albertelli M; Barbieri F; Brue T; Niccoli P; Delpero JR; Garcia S; Ferone D; Florio T; Moutardier V; Poizat F; Barlier A; Gerard C
Oncotarget; 2017 Jun; 8(25):41044-41063. PubMed ID: 28454119
[TBL] [Abstract][Full Text] [Related]
35. The pivotal role of mammalian target of rapamycin inhibition in the treatment of patients with neuroendocrine tumors.
Phan AT; Dave B
Cancer Med; 2016 Oct; 5(10):2953-2964. PubMed ID: 27539383
[TBL] [Abstract][Full Text] [Related]
36. Overcoming resistance to rapalogs in gliomas by combinatory therapies.
Grzmil M; Hemmings BA
Biochim Biophys Acta; 2013 Jul; 1834(7):1371-80. PubMed ID: 23395884
[TBL] [Abstract][Full Text] [Related]
37. The Role of mTOR in Neuroendocrine Tumors: Future Cornerstone of a Winning Strategy?
Lamberti G; Brighi N; Maggio I; Manuzzi L; Peterle C; Ambrosini V; Ricci C; Casadei R; Campana D
Int J Mol Sci; 2018 Mar; 19(3):. PubMed ID: 29509701
[TBL] [Abstract][Full Text] [Related]
38. CC-223, a Potent and Selective Inhibitor of mTOR Kinase: In Vitro and In Vivo Characterization.
Mortensen DS; Fultz KE; Xu S; Xu W; Packard G; Khambatta G; Gamez JC; Leisten J; Zhao J; Apuy J; Ghoreishi K; Hickman M; Narla RK; Bissonette R; Richardson S; Peng SX; Perrin-Ninkovic S; Tran T; Shi T; Yang WQ; Tong Z; Cathers BE; Moghaddam MF; Canan SS; Worland P; Sankar S; Raymon HK
Mol Cancer Ther; 2015 Jun; 14(6):1295-305. PubMed ID: 25855786
[TBL] [Abstract][Full Text] [Related]
39. Inhibition of mTOR in carcinoid tumors.
Grozinsky-Glasberg S; Pavel M
Target Oncol; 2012 Sep; 7(3):189-95. PubMed ID: 22886906
[TBL] [Abstract][Full Text] [Related]
40. Pancreatic Neuroendocrine Tumors and EMT Behavior Are Driven by the CSC Marker DCLK1.
Ikezono Y; Koga H; Akiba J; Abe M; Yoshida T; Wada F; Nakamura T; Iwamoto H; Masuda A; Sakaue T; Yano H; Tsuruta O; Torimura T
Mol Cancer Res; 2017 Jun; 15(6):744-752. PubMed ID: 28179411
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]